Provectus Biopharmaceuticals shares 2026 meeting update

Provectus Biopharmaceuticals, Inc. filed a current report describing information to be shared at its June 18, 2026 annual meeting of stockholders.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Provectus Biopharmaceuticals, Inc. filed a current report describing information to be shared at its June 18, 2026 annual meeting of stockholders. The company plans to update stockholders on clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities.

The accompanying 2026 Annual Meeting of Stockholders presentation slides are attached as Exhibit 99.1. This material is furnished under Regulation FD and is not deemed filed under the Securities Exchange Act of 1934.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Annual meeting date: June 18, 2026 Presentation exhibit: Exhibit 99.1 Cover page data file: Exhibit 104

3 metrics

Annual meeting date June 18, 2026 Date of 2026 Annual Meeting of Stockholders

Presentation exhibit Exhibit 99.1 2026 Annual Meeting of Stockholders presentation slides

Cover page data file Exhibit 104 Cover Page Interactive Data File with inline XBRL tags

Key Terms

Regulation FD Disclosure, emerging growth company, inline XBRL

3 terms

Regulation FD Disclosure regulatory

"Item 7.01. Regulation FD Disclosure. During its annual meeting of stockholders..."

Regulation FD disclosure requires public companies to share important, market-moving information with everyone at the same time instead of tipping off analysts or large investors first. Think of it as making sure all players on a field hear the same announcement simultaneously; that fairness helps investors trust that stock prices reflect the same information and reduces the risk of sudden, unfair trading advantages or regulatory penalties for selective leaks.

emerging growth company regulatory

"Emerging growth company Item 7.01. Regulation FD Disclosure."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

inline XBRL technical

"Cover Page Interactive Date File (the cover page XBRL tags are embedded within the inline XBRL document)."

Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Provectus Biopharmaceuticals (PVCT) disclose in the June 18, 2026 8-K?

Provectus Biopharmaceuticals disclosed the topics to be covered at its June 18, 2026 annual stockholder meeting. It will update investors on clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities, supported by presentation slides furnished as Exhibit 99.1.

What is included in Provectus Biopharmaceuticals (PVCT) Exhibit 99.1?

Exhibit 99.1 contains Provectus Biopharmaceuticals’ 2026 Annual Meeting of Stockholders presentation slides. These slides support management’s update on clinical programs, regulatory matters, discovery work, manufacturing, intellectual property, business development, and corporate development that will be presented at the annual meeting.

How is the Provectus Biopharmaceuticals (PVCT) annual meeting information treated under SEC rules?

The annual meeting information, including Exhibit 99.1, is furnished under Regulation FD and not deemed filed under the Exchange Act. This treatment limits its use for certain liability provisions while still making the information publicly available to all investors simultaneously.

When is the Provectus Biopharmaceuticals (PVCT) 2026 annual stockholder meeting held?

The 2026 annual meeting of stockholders for Provectus Biopharmaceuticals is held on June 18, 2026. At this meeting, management plans to present detailed updates across clinical development, regulatory affairs, discovery, manufacturing, intellectual property, business development, and corporate development activities.

Does the June 18, 2026 Provectus Biopharmaceuticals 8-K report new financial results?

The June 18, 2026 report focuses on Regulation FD disclosure tied to the annual meeting presentation. It describes planned updates on operations and development activities, and attaches the meeting slides as Exhibit 99.1, rather than presenting new financial statements or earnings data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/18/2026 - 02:59 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 18, 2026

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

Delaware	001-36457	90-0031917
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

800 S. Gay Street, Suite 1610, Knoxville, Tennessee 37929

(Address of Principal Executive Offices) (Zip Code)

(866) 594-5999

(Registrant’s Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Title of each class		Trading Symbol(s)		Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

During its annual meeting of stockholders to be held on June 18, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) will provide an update about the Company’s clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business development, and corporate development activities.

A copy of the Company’s 2026 Annual Meeting of Stockholders presentation slides is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		2026 Annual Meeting of Stockholders presentation slides
104		Cover Page Interactive Date File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 18, 2026